CONMED CorpCNMDEarnings & Financial Report
The CONMED Corporation is a publicly traded American manufacturer of medical equipment and surgical devices, primarily in the orthopedic, laparoscopic and general surgery, and patient care areas. CONMED's headquarters is in Largo, Florida. Prior to July 2022, it was in Utica, New York. CONMED embraces a people-first culture that starts with a mission to support their healthcare partners and the patients they serve. They have manufacturing facilities in the United States and Mexico, offices in...
CNMD Q4 FY2025 Key Financial Metrics
Revenue
$373.2M
Gross Profit
$218.3M
Operating Profit
$36.6M
Net Profit
N/A
Gross Margin
58.5%
Operating Margin
9.8%
Net Margin
N/A
YoY Growth
7.9%
EPS
$0.54
CONMED Corp Q4 FY2025 Financial Summary
CONMED Corp reported revenue of $373.2M (up 7.9% YoY) for Q4 FY2025, with a net profit of N/A (N/A margin). Cost of goods sold was $154.9M, operating expenses totaled $181.7M.
Key Financial Metrics
| Total Revenue | $373.2M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 58.5% |
| Operating Margin | 9.8% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
CONMED Corp Q4 FY2025 revenue of $373.2M breaks down across 2 segments, led by Transferred At Point In Time at $358.5M (96.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Transferred At Point In Time | $358.5M | 96.1% |
| Transferred Over Time | $14.7M | 3.9% |
CONMED Corp Revenue by Segment — Quarterly Trend
CONMED Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as Transferred At Point In Time and Transferred Over Time) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Transferred At Point In Time | $358.5M | $323.8M | $328.4M | $308.1M |
| Transferred Over Time | $14.7M | $14.1M | $13.9M | $13.2M |
CONMED Corp Annual Revenue by Year
CONMED Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.4B).
CONMED Corp Quarterly Revenue & Net Profit History
CONMED Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $373.2M | +7.9% | N/A | N/A |
| Q3 FY2025 | $337.9M | +6.7% | $2.9M | 0.8% |
| Q2 FY2025 | $342.3M | +3.1% | $21.4M | 6.3% |
| Q1 FY2025 | $321.3M | +2.9% | $6.0M | 1.9% |
| Q4 FY2024 | $345.9M | +5.8% | N/A | N/A |
| Q3 FY2024 | $316.7M | +4.0% | $49.0M | 15.5% |
| Q2 FY2024 | $332.1M | +4.5% | $30.0M | 9.0% |
| Q1 FY2024 | $312.3M | +5.7% | $19.7M | 6.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $312.3M | $332.1M | $316.7M | $345.9M | $321.3M | $342.3M | $337.9M | $373.2M |
| YoY Growth | 5.7% | 4.5% | 4.0% | 5.8% | 2.9% | 3.1% | 6.7% | 7.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.31B | $2.29B | $2.32B | $2.31B | $2.30B | $2.33B | $2.32B | $2.33B |
| Liabilities | $1.45B | $1.40B | $1.38B | $1.34B | $1.32B | $1.33B | $1.31B | $1.29B |
| Equity | $854.7M | $881.8M | $932.9M | $962.7M | $977.6M | $1.00B | $1.01B | $1.03B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $29.1M | $43.3M | $51.2M | $43.3M | $41.5M | $29.1M | $53.7M | $46.3M |